Document Detail


Hypersensitivity reactions to teniposide (VM-26): an analysis.
MedLine Citation:
PMID:  3525769     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
An analysis of hypersensitivity reactions to teniposide was approached using three methods: investigator survey, adverse drug reaction analysis, and literature search. By the survey method, hypersensitivity incidence was 6.5% with the majority of the reactions (82%) occurring in brain tumor or neuroblastoma patients. By the second method, 43 cases of hypersensitivity that were reported to the National Cancer Institute (NCI) between January 1983 and October 1985 were analyzed in detail. Reaction onset was unpredictable according to the number of drug doses. The majority of the patients (65%) experiencing the reaction had neuroblastoma or brain tumors, and these patients also tended to react earlier in the course of drug administration than those with hematologic malignancies. Clinical presentation was not correlated with the patient's diagnosis. All patients recovered. However, only six of 13 were successfully rechallenged with the drug. The third approach, the literature search, provided information on 82 hypersensitivity reactions among 2,250 patients (3.6% incidence). Forty-five percent of these reactions were linked to neuroblastoma or brain tumor patients. The analysis of hypersensitivity to teniposide by these three methods provides insight into the true incidence of hypersensitivity reactions in the general patient population. The frequency of the reactions is substantially higher in patients with neuroblastoma and brain tumors. This population should be considered for future trials of aggressive prophylactic therapy.
Authors:
P J O'Dwyer; S A King; C L Fortner; B Leyland-Jones
Related Documents :
14971719 - Characteristics, clinical effect profile and tolerability of a nasal spray preparation ...
3306889 - No evidence of hypersensitivity to dental restorative metals in oral lichen planus.
6196389 - Anaphylaxis after hymenoptera stings in three patients with urticaria pigmentosa.
476909 - Natural history of allergy to hymenoptera.
6578889 - Specific desensitization in 'aspirin-sensitive' urticaria; plasma prostaglandin levels ...
7451779 - Further studies on the safety of polymerized antigens for immunotherapy.
18317299 - Striatal dopamine transporter abnormalities in patients with essential tremor.
11677749 - Vestibular diagnosis as prognostic indicator in sudden hearing loss with vertigo.
21957469 - Incidence and severity of coronary artery disease in patients with atrial fibrillation ...
Publication Detail:
Type:  Bibliography; Case Reports; Journal Article    
Journal Detail:
Title:  Journal of clinical oncology : official journal of the American Society of Clinical Oncology     Volume:  4     ISSN:  0732-183X     ISO Abbreviation:  J. Clin. Oncol.     Publication Date:  1986 Aug 
Date Detail:
Created Date:  1986-09-17     Completed Date:  1986-09-17     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  8309333     Medline TA:  J Clin Oncol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  1262-9     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Aged
Bibliography as Topic
Blood Pressure / drug effects
Brain Neoplasms / drug therapy
Child
Child, Preschool
Data Collection / methods
Drug Evaluation
Drug Hypersensitivity*
Edema / chemically induced
Humans
Hypersensitivity, Immediate / chemically induced*
Infant
Leukemia / drug therapy
Male
Middle Aged
Neuroblastoma / drug therapy
Podophyllotoxin / analogs & derivatives*
Questionnaires
Teniposide / adverse effects*
Urticaria / chemically induced
Chemical
Reg. No./Substance:
29767-20-2/Teniposide; 518-28-5/Podophyllotoxin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Improved survival duration with combination chemotherapy induction for multiple myeloma: a Southwest...
Next Document:  A phase I trial of spirohydantoin mustard (NSC 172112) in patients with advanced cancer.